Mechanisms underlying the QT interval-prolonging - Effects of sevoflurane and its interactions with other QT-prolonging drugs

被引:44
|
作者
Kang, JS [1 ]
Reynolds, WP [1 ]
Chen, XL [1 ]
Ji, JZ [1 ]
Wang, HG [1 ]
Rampe, DE [1 ]
机构
[1] Sanofi Aventis, Dept Drug Safety Evaluat, US Safety Pharmacol, Bridgewater, NJ 08807 USA
关键词
D O I
10.1097/00000542-200605000-00018
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Sevoflurane prolongs ventricular repolarization in patients, but the mechanisms are not fully characterized. The effects of sevoflurane on many cloned human cardiac ion channels have not been studied, and the interactions between sevoflurane and other drugs that prolong cardiac repolarization have not been detailed. Methods: The effects of sevoflurane on action potentials and L-type Ca2+ channels in guinea pig myocytes were examined. Sevofluarane's effects on cloned human cardiac K+ channels and the cloned human cardiac Na+ channel were studied. The consequences of combining sevoflurane and the class III antiarrhythmic drugs sotalol or dofetilide on action potential duration were also examined. Results: Sevoflurane produced an increase in action potential duration at concentrations of 0.3-1 m(M). Contrary to most drugs that delay ventricular repolarization, sevoflurane was without effect on the human ether-a-go-go-related gene cardiac potassium channel but instead produced a reduction in KvLQT1/minK K+ channel currents and inhibited the Kv4.3 K+ channel by speeding its apparent rate of inactivation. Sevoflurane had little effect on Na+ and Ca2+ channel currents at concentrations of 1 mm or less. When the authors coadministered sevoflurane with sotalol or dofetilide, synergistic effects on repolarization were observed, resulting in large increases in action potential duration (up to 66%). Conclusion: Prolonged ventricular repolarization observed with administration of sevoflurane results from inhibition of KvLQT1/minK and Kv4.3 cardiac K+ channels. Combining sevoflurane with class III antiarrhythmic drugs results in supra-additive effects on action potential duration. The results indicate that sevoflurane, when administered with this class of drug, could result in excessive delays in ventricular repolarization. The results suggest the need for further clinical studies.
引用
收藏
页码:1015 / 1022
页数:8
相关论文
共 50 条
  • [21] Assessment of QT-prolonging drugs in the isolated normal and failing rabbit hearts
    Kijtawornrat, Anusak
    Sawangkoon, Suwanakiet
    Hamlin, Robert L.
    JOURNAL OF TOXICOLOGICAL SCIENCES, 2012, 37 (03): : 455 - 462
  • [22] Drug interactions with QT-prolonging antibiotics: an epidemiological study in community pharmacies
    Eline Vandael
    Chantal Leirs
    Margaux Claes
    Amelie Matheve
    Elien Verbeeck
    Delphine Demeyer
    Veerle Foulon
    Archives of Public Health, 73 (Suppl 1)
  • [23] Incidence of drug-drug interactions of QT-prolonging drugs in an onco-hematological outpatient
    Fort, E.
    Otero, S.
    Moliner, P.
    Bleda, C.
    Prats, J.
    Nadal, E.
    Palmero, R.
    Jimenez, L.
    Piulats, J. M.
    Rey, M.
    Fontanals, S.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2726 - 2726
  • [24] Risk Management of QT-prolonging Drugs by Community Pharmacists by Using a Mobile Electrocardiograph
    Shinozaki, Kohki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2010, 130 (11): : 1597 - 1601
  • [25] Effects of QT-prolonging drugs on the non-clinical assay models: Comparison with clinical study
    Sugiyama, Atsushi
    Hoshiai, Kiyotaka
    Nakamura, Yuji
    Sakamoto, Kengo
    Wakasa, Yoshio
    Morikawa, Hiroshi
    Hayashi, Takashi
    Muto, Norio
    Ulit, Ana Marie-V.
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2008, 106 : 26P - 26P
  • [26] Assessment of inappropriate prescribing of QT interval-prolonging drugs in end-stage renal disease patients in Jordan
    Ahmad Z. Al Meslamani
    Dania Abu-Naser
    Derar H. Abdel-Qader
    Mohammed S. Aljamal
    Mohammed A Alsharif
    Mohamed Ahmed Mohammed Alshrahili
    Nadia Al Mazrouei
    Osama Mohamed Ibrahim
    Drugs & Therapy Perspectives, 2021, 37 : 87 - 93
  • [27] Potential QT-prolonging drug-drug interactions in cardiovascular disease patients
    Kovacevic, Milena
    Culafic, Milica
    Jovanovic, Marija
    Kovacevic, Sandra Vezmar
    Vucicevic, Katarina
    Miljkovic, Branislava
    Stevanovic, Predrag
    Radovanovic, Slavica
    BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2025, 61
  • [28] Hydroxychloroquine Alone Does Not Increase QTc in the Absence of Other QT-prolonging Medications
    Wang, Haihui
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3673 - 3674
  • [29] Assessment of inappropriate prescribing of QT interval-prolonging drugs in end-stage renal disease patients in Jordan
    Al Meslamani, Ahmad Z.
    Abu-Naser, Dania
    Abdel-Qader, Derar H.
    Aljamal, Mohammed S.
    Alsharif, Mohammed A.
    Alshrahili, Mohamed Ahmed Mohammed
    Al Mazrouei, Nadia
    Ibrahim, Osama Mohamed
    DRUGS & THERAPY PERSPECTIVES, 2021, 37 (02) : 87 - 93
  • [30] A computational analysis of the effect of sevoflurane in a human ventricular cell model of long QT syndrome: Importance of repolarization reserve in the QT-prolonging effect of sevoflurane
    Kojima, Akiko
    Fukushima, Yutaka
    Itoh, Hideki
    Imoto, Keiji
    Matsuura, Hiroshi
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2020, 883